argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-06-25)
EUR 781.80+4.43%

argenx SE
UMushroom community rating:

star star star star star
4.86 3 votes No rating yet
NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

61.8%1Y
115%3Y
194%5Y

Performance

33.3%1Y
40.1%3Y
38.5%5Y

Volatility

Market cap

55307 M

Market cap (USD)

Daily traded volume (Shares)

126,313

Daily traded volume (Shares)

1 day high/low

600 / 594.2

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.86

3 votes
Performance:
starstarstarstarstar
4.71
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
4.86
Nature:
starstarstarstarstar
3.57
Laura Sofie Tohver
United Kingdom, 11 Nov 2025
star star star star star
Emerging technology and nice returns
Viktor Stockel
Switzerland, 30 Oct 2025
star star star star star
Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.
Claudia Stadelmann
Switzerland, 05 Mar 2025
star star star star star
Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

Flywire Corp
Flywire Corp Flywire Corp Valor: 111444572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.06%USD 16.88
Sportradar Group AG
Sportradar Group AG Sportradar Group AG Valor: 113423966
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.23%USD 14.45
Salesforce Inc
Salesforce Inc Salesforce Inc Valor: 1755645
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.68%USD 150.19
NAPCO Security Technologies Inc
NAPCO Security Technologies Inc NAPCO Security Technologies Inc Valor: 954486
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%USD 37.42
Power Integrations Inc
Power Integrations Inc Power Integrations Inc Valor: 234802
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.60%USD 84.81
Cirrus Logic Inc
Cirrus Logic Inc Cirrus Logic Inc Valor: 918510
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.34%USD 153.98
Evolution AB
Evolution AB Evolution AB Valor: 48025470
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.57%SEK 664.80
10x Genomics Inc
10x Genomics Inc 10x Genomics Inc Valor: 49648927
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.27%USD 35.73
Tower Semiconductor Ltd
Tower Semiconductor Ltd Tower Semiconductor Ltd Valor: 280630
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.98%USD 269.88
TEMENOS LTD
TEMENOS LTD TEMENOS LTD Valor: 1245391
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.37%CHF 64.75